Revenue
2025
POMDOCTOR Ltd (POM)
Price$0.8300Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $57.2M | — | — | — |
| Gross profit | $7.5M | — | — | — |
| Gross margin | 13.07% | — | — | — |
| Research & development | $1.8M | — | — | — |
| Operating expenses | $24.4M | — | — | — |
| Operating income | −$17.0M | — | — | — |
| Operating margin | −29.67% | — | — | — |
| EBITDA | −$16.9M | — | — | — |
| EBITDA margin | −29.63% | — | — | — |
| Net income | −$18.7M | — | — | — |
| Net profit margin | −32.74% | — | — | — |
| Basic EPSper basic share | -$3.14 | — | — | — |
| Diluted EPSper diluted share | -$3.14 | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
CITADEL ADVISORS LLC | 21.27K |
UBS Group AG | 3.46K |
Caitong International Asset Management Co., Ltd | 893 |
Arax Advisory Partners | 722 |
Steward Partners Investment Advisory, LLC | 111 |
RHUMBLINE ADVISERS | 41 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data